IL2 and cancer: The underlying pathophysiology is complicated, involving the suppression of monocytes, cytotoxic T cells, and NK cell activity, as well as the inhibition of interleukin-2(IL-2) production [24,25], whose roles are crucial in the process of cancer cell recognition and eradication.